The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells.
Open accessAbstract
The folate antagonist methotrexate (MTX) is extensively used in graft-versus-host disease, rheumatoid arthritis, and other chronic inflammatory disorders. In addition to its antiinflammatory activity associated with increased release of adenosine, MTX exerts antiproliferative properties by inhibition of dihydrofolate reductase and other folate-dependent enzymes. However, the mechanisms of immunosuppressive properties associated with low-dose MTX treatments are still elusive. We report here that MTX (0.1-10 microM) induces apoptosis of in vitro activated T cells from human peripheral blood. PBL exposed to MTX for 8 h, then activated in drug-free medium, underwent apoptosis, which was completely abrogated by addition of folinic acid or thymidine. Apoptosis of activated T cells did not require interaction between CD95 (Fas, APO-1) and its ligand, and adenosine release accounted for only a small part of this MTX activity. Apoptosis required progression of activated T cells to the S phase of the cell cycle, as it was prevented by drugs or antibodies that interfere with IL-2 synthesis or signaling pathways. MTX achieved clonal deletion of activated T cells in mixed lymphocyte reactions. Finally, in vitro activation of PBL taken from rheumatoid arthritis patients after MTX injection resulted in apoptosis. Altogether, the data demonstrate that MTX can selectively delete activated peripheral blood T cells by a CD95-independent pathway. This property could be used as a new pharmacological end point to optimize dosage and timing of MTX administration. It may account for the immunosuppressive effects of low-dose MTX treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
Koopman, G., Reutelingsperger, C., Kuijten, G., Keehnen, R., Pals, S., & van Oers, M. (1994) · Blood · doi:10.1182/blood.v84.5.1415.1415 · Cited by 2,681
Storb, R., Deeg, H. J., Whitehead, J., Appelbaum, F., Beatty, P., Bensinger, W., Buckner, C. D., Clift, R., Doney, K., Farewell, V., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603203141201 · Cited by 1,411
Apoptosis in cancer therapy: Crossing the threshold
Fisher, D. E. (1994) · Cell · doi:10.1016/0092-8674(94)90518-5 · Cited by 1,315
Mutations in Fas Associated with Human Lymphoproliferative Syndrome and Autoimmunity
Rieux-Laucat, F., Le Deist, F., Hivroz, C., Roberts, I. A. G., Debatin, K. M., Fischer, A., & de Villartay, J. P. (1995) · Science · doi:10.1126/science.7539157 · Cited by 1,297
Zamzami, N., Marchetti, P., Castedo, M., Zanin, C., Vayssière, J. L., Petit, P. X., & Kroemer, G. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.5.1661 · Cited by 1,166
Gorczyca, W., GONG, J., & Darżynkiewicz, Z. (1993) · PubMed · Cited by 982
Friesen, C., Herr, I., Krammer, P. H., & Debatin, K.-M. (1996) · Nature Medicine · doi:10.1038/nm0596-574 · Cited by 974
Efficacy of Low-Dose Methotrexate in Rheumatoid Arthritis
Weinblatt, M. E., Coblyn, J. S., Fox, D. A., Fraser, P. A., Holdsworth, D. E., Glass, D. N., & Trentham, D. E. (1985) · New England Journal of Medicine · doi:10.1056/nejm198503283121303 · Cited by 872
Müller, M., Strand, S., Hug, H., Heinemann, E. M., Walczak, H., Hofmann, W. J., Stremmel, W., Krammer, P. H., & Galle, P. R. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119174 · Cited by 748
Cited by
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
Anti-TNFα Therapy of Rheumatoid Arthritis: What Have We Learned?
Feldmann, M., & Maini, R. N. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.163 · Cited by 1,257
T cell apoptosis by tryptophan catabolism
Fallarino, F., Grohmann, U., Vacca, C., Bianchi, R., Orabona, C., Spreca, A., Fioretti, M. C., & Puccetti, P. (2002) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401073 · Cited by 1,022
Van den Brande, J. M. H., Braat, H., van den Brink, G. R., Versteeg, H. H., Bauer, C. A., Hoedemaeker, I., van Montfrans, C., Hommes, D. W., Peppelenbosch, M. P., & van Deventer, S. J. H. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00382-2 · Cited by 723
Development of anti-TNF therapy for rheumatoid arthritis
Feldmann, M. (2002) · Nature Reviews Immunology · doi:10.1038/nri802 · Cited by 673
Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease
ten Hove, T. (2002) · Gut · doi:10.1136/gut.50.2.206 · Cited by 545
Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis
Cronstein, B. N. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.3 · Cited by 535
Inflammatory Skin Diseases, T Cells, and Immune Surveillance
Robert, C., & Kupper, T. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912093412407 · Cited by 475
Methotrexate an Old Drug with New Tricks
Bedoui, Y., Guillot, X., Sélambarom, J., Guiraud, P., Giry, C., Jaffar-Bandjee, M. C., Ralandison, S., & Gasque, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205023 · Cited by 471
Nucleotide metabolism: a pan-cancer metabolic dependency
Mullen, N. J., & Singh, P. K. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00557-7 · Cited by 466
Methotrexate—how does it really work?
Chan, E. S. L., & Cronstein, B. N. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.5 · Cited by 459
Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis
CUTOLO, M., SULLI, A., PIZZORNI, C., SERIOLO, B., & STRAUB, R. H. (2001) · Annals of the Rheumatic Diseases · doi:10.1136/ard.60.8.729 · Cited by 433
Mechanisms of action of methotrexate
Genestier, L., Paillot, R., Quemeneur, L., Izeradjene, K., & Revillard, J.-P. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)00189-2 · Cited by 424
Self-citationApoptosis as a therapeutic tool in rheumatoid arthritis
Pope, R. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri846 · Cited by 401
Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers
Brown, P. M., Pratt, A. G., & Isaacs, J. D. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.175 · Cited by 382
Immunosuppressive drugs: the first 50 years and a glance forward
Allison, A. C. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)00186-7 · Cited by 350
Methotrexate in Rheumatoid Arthritis
(1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-418 · Cited by 345
Smoking and Rheumatoid Arthritis
Chang, K., Yang, S., Kim, S., Han, K., Park, S., & Shin, J. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151222279 · Cited by 337
Koźmiński, P., Halik, P. K., Chesori, R., & Gniazdowska, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103483 · Cited by 326
Weinblatt, M. E., Kremer, J. M., Coblyn, J. S., Maier, A. L., Helfgott, S. M., Morrell, M., Byrne, V. M., Kaymakcian, M. V., & Strand, V. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199907)42:7<1322::aid-anr4>3.0.co;2-p · Cited by 286
Prevalence of Joint Disease in Patients with Psoriasis: Implications for Therapy
Zachariae, H. (2003) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200304070-00001 · Cited by 272
The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy
Schaer, D. A., Geeganage, S., Amaladas, N., Lu, Z. H., Rasmussen, E. R., Sonyi, A., Chin, D., Capen, A., Li, Y., Meyer, C. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0433 · Cited by 132
Metadata
- Authors
- Genestier, L., Paillot, R., Fournel, S., Ferraro, C., Miossec, P., & Revillard, J. P.
- Venue
- Journal of Clinical Investigation
- Published
- 1998-07-15
- Volume
- 102
- Issue
- 2
- Pages
- 322-328
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2072829987
- Cited by
- 459
- References
- 28
- FWCI
- 6.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.